Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness.
作者信息
Sheehan Mark
出版信息
BMJ. 2005 Nov 12;331(7525):1144-5. doi: 10.1136/bmj.331.7525.1144-c.
Abstract
摘要
相似文献
1
Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness.
BMJ. 2005 Nov 12;331(7525):1144-5. doi: 10.1136/bmj.331.7525.1144-c.
2
Orphan drugs and the NHS: should we value rarity?
BMJ. 2005 Oct 29;331(7523):1016-9. doi: 10.1136/bmj.331.7523.1016.
3
Orphan drugs and the NHS: consider whom drug regulation is designed to protect.
BMJ. 2005 Nov 12;331(7525):1144. doi: 10.1136/bmj.331.7525.1144-b.
4
Societal Preferences for Funding Orphan Drugs in the United Kingdom: An Application of Person Trade-Off and Discrete Choice Experiment Methods.
Value Health. 2018 May;21(5):538-546. doi: 10.1016/j.jval.2017.12.026.
5
Drugs for exceptionally rare diseases: do they deserve special status for funding?
QJM. 2005 Nov;98(11):829-36. doi: 10.1093/qjmed/hci128. Epub 2005 Oct 3.
6
Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum.
Appl Health Econ Health Policy. 2013 Feb;11(1):1-3. doi: 10.1007/s40258-012-0004-y.
7
[Orphan drugs: drugs for rare diseases].
Dtsch Med Wochenschr. 2010 May;135(18):p17.
8
Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.
BioDrugs. 2015 Aug;29(4):259-74. doi: 10.1007/s40259-015-0135-4.
9
Limits on use of health economic assessments for rare diseases.
QJM. 2014 Mar;107(3):241-5. doi: 10.1093/qjmed/hcu016. Epub 2014 Jan 22.
10
[Orphan drugs: towards an economic evaluation].
Rev Prat. 2012 Jan;62(1):91-4.
引用本文的文献
1
Debates over orphan drug pricing: a meta-narrative literature review.
Orphanet J Rare Dis. 2025 Mar 7;20(1):107. doi: 10.1186/s13023-025-03634-2.
2
A systematic review of moral reasons on orphan drug reimbursement.
Orphanet J Rare Dis. 2021 Jun 30;16(1):292. doi: 10.1186/s13023-021-01925-y.
3
Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Orphanet J Rare Dis. 2016 Jun 4;11(1):72. doi: 10.1186/s13023-016-0455-6.
4
Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.
Orphanet J Rare Dis. 2016 Mar 10;11:23. doi: 10.1186/s13023-016-0388-0.
本文引用的文献
1
Orphan drugs and the NHS: should we value rarity?
BMJ. 2005 Oct 29;331(7523):1016-9. doi: 10.1136/bmj.331.7523.1016.
Zotero 插件